Insulet (NASDAQ:PODD) Reports Upbeat Q1 CY2026, Stock SoarsInsulin delivery company Insulet Corporation (
NASDAQ:PODD) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 33.9% year on...
Insulet Reports First Quarter 2026 Results
Insulet Corporation (
NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its financial results for the three months ended March 31, 2026.
Insulet Unveils 2025 Sustainability Report Highlighting Strong Momentum Across Key Priorities
Insulet Corporation (
NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the publication of its 2025 Sustainability Report, showcasing progress across its operations, products, people, and community. The report underscores how Insulet’s sustainability strategy continues to strengthen its mission of transforming life for people with diabetes while preserving the health of our planet.
Earnings To Watch: Insulet (PODD) Reports Q1 Results TomorrowInsulin delivery company Insulet Corporation (
NASDAQ:PODD) will be reporting earnings this Wednesday morning. Here’s what investors should know. Insulet beat...
Insulet Initiates EVOLVE Pivotal Study to Advance Fully Closed-Loop Automated Insulin Delivery System for Type 2 Diabetes
Insulet Corporation (
NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, has enrolled the first participant in a pivotal study for its fully closed-loop (FCL)A automated insulin delivery (AID) system for type 2 diabetes (T2D). FCL for T2D is a breakthrough innovation intended to further improve glycemic outcomes with less burden for users across diverse care settings. That includes eliminating user interactions for bolusing and mealtime announcements for people with T2D as well as settings to start and onboard.
Insulet to Participate in BofA Securities 2026 Health Care Conference
Insulet Corporation (
NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the BofA Securities 2026 Health Care Conference in Las Vegas on Wednesday, May 13, 2026 at 9:20 a.m. (Pacific Time).
1 Oversold Stock Primed to Rebound and 2 We IgnoreHitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround story or confirmation that a co...
2 of Wall Street’s Favorite Stocks for Long-Term Investors and 1 We Turn DownThe stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insulet Corporation - PODDNEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Insulet Corporation (“Insulet” or the “Company”) (
NASDAQ: PODD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insulet Corporation - PODDNEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Insulet Corporation (“Insulet” or the “Company”) (
NASDAQ: PODD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
2 High-Flying Stocks to Own for Decades and 1 We Turn DownExpensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lo...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insulet Corporation - PODDNEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Insulet Corporation (“Insulet” or the “Company”) (
NASDAQ: PODD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Insulet (PODD): 3 Reasons We Love This StockWhat a brutal six months it’s been for Insulet. The stock has dropped 33.8% and now trades at $204.57, rattling many shareholders. This may have investors wo...
Eli Lilly Secures Landmark FDA Approval for Oral Weight-Loss Pill, Sending Shares SoaringShares of Eli Lilly and Company (
NYSE: LLY) surged 3.8% on Wednesday following the milestone FDA approval of Foundayo (orforglipron), the first once-daily oral weight-loss pill that does not require strict fasting or water intake restrictions. The approval, which came months ahead of initial analyst expectations, marks a pivotal
Insulet to Announce First Quarter 2026 Financial Results on May 6, 2026
Insulet Corporation (
NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the first quarter of 2026 on Wednesday, May 6, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insulet Corporation - PODDNEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Insulet Corporation (“Insulet” or the “Company”) (
NASDAQ: PODD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
